Opdivo, the immunotherapy drug that has been developed by Bristol-Myers Squibb, has showed a promising effect for treatment of melanoma with few toxic side effects comparing to the standard chemotherapy. In the Phase III clinical trial, tumors was found to shrink in patient given Opdivo. Moreover, the duration of the response was found to be more extended, more than six months, in comparison to 3.6 months for other therapies. Opdivo, or nivolumab, works by blocking the Programmed Death receptor (PD-1), a protein that used by tumors to elude disease-fighting cells of the immune system. Observing this trend of chemotherapy development, how would you interpret that on the clinical practice?
For more reading, please see Reuters.
Image courtesy of [Dream Designs] / FreeDigitalPhotos.net